Connect your AI

Nektar Therapeutics NKTR Cumulative Cost Basis

Cumulative Cost Basis at other companies

AmgenAMGN

——

Regeneron PharmaceuticalsREGN

——

ImmunityBio, Inc.IBRX

——

IncyteINCY

——

Arcus BiosciencesRCUS

——

Johnson & JohnsonJNJ

——

Other financials

Income statement

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

Market cap$2.19B+1,531%

Profitability

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Nektar Therapeutics's cumulative cost basis?: Nektar Therapeutics (NKTR) reported cumulative cost basis of $695.19M in Q1 2026.